These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
943 related articles for article (PubMed ID: 19108785)
1. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Deremer DL; Ustun C; Natarajan K Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785 [TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
3. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Usuki K; Tojo A; Maeda Y; Kobayashi Y; Matsuda A; Ohyashiki K; Nakaseko C; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Okamoto S; Oritani K; Okada M; Usui N; Nagai T; Amagasaki T; Wanajo A; Naoe T Int J Hematol; 2012 Apr; 95(4):409-19. PubMed ID: 22359103 [TBL] [Abstract][Full Text] [Related]
5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389 [TBL] [Abstract][Full Text] [Related]
6. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337 [TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017 [TBL] [Abstract][Full Text] [Related]
8. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Tojo A; Usuki K; Urabe A; Maeda Y; Kobayashi Y; Jinnai I; Ohyashiki K; Nishimura M; Kawaguchi T; Tanaka H; Miyamura K; Miyazaki Y; Hughes T; Branford S; Okamoto S; Ishikawa J; Okada M; Usui N; Tanii H; Amagasaki T; Natori H; Naoe T Int J Hematol; 2009 Jun; 89(5):679-88. PubMed ID: 19449194 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia]. Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663 [TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226 [TBL] [Abstract][Full Text] [Related]
11. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504 [TBL] [Abstract][Full Text] [Related]
12. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041 [TBL] [Abstract][Full Text] [Related]
13. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Shamroe CL; Comeau JM Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264 [TBL] [Abstract][Full Text] [Related]
14. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466 [TBL] [Abstract][Full Text] [Related]
15. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia. Stansfield L; Hughes TE; Walsh-Chocolaad TL Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109 [TBL] [Abstract][Full Text] [Related]
16. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Stein B; Smith BD Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492 [TBL] [Abstract][Full Text] [Related]
17. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406 [TBL] [Abstract][Full Text] [Related]
18. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Jarkowski A; Sweeney RP Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997 [TBL] [Abstract][Full Text] [Related]